Key facts
- Medcura’s last known valuation is $112.0M (Jul 2025).
- It has raised $55.9M across 4 recorded rounds; the latest was Early Stage VC ($28.5M) in Apr 2025.
- Notable investors include US National Science Foundation, United States Department of War, TEDCO, New York Angels, Robin Hood Ventures — 18 tracked in total.
- Medcura has filed 5 Form Ds with the SEC since 2020, most recently Jul 2025 ($28.5M sold to 174 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Medcura
Funding rounds
4 roundsAbout Medcura
Developer of biopolymer-based hemostatic device designed to manage surgical bleeding in clinical, military, and consumer environments. The company's device utilizes hydrophobically modified natural biomaterials that mechanically adhere to bleeding sites without swelling, reduce risk in confined anatomical spaces, maintain structural integrity during application, and offer cost-effective bleeding control, enabling surgeons and healthcare providers to improve safety, reduce complications, and optimize procedural efficiency.
- Sector
- Healthcare
- HQ
- Riverdale, MD, United States
- Founded
- 2007
- Employees
- 35
- Website
- medcurainc.com/
- Ownership
- Privately Held (backing)
Medcura doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medcura shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medcura in its N-PORT filings yet. We sweep new filings monthly.